| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., October 29, 2026/PRNewswire/ Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies... |
| 29 Oct 2026 | 10-Q |
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) the type of information that the registrant customarily and actually treats as private or confidential. Excluded information ... |
| 17 Sep 2026 |
Form 4: Gentile Kimberly, SVP, Clinical Operations
Granted 1,000 Stock Options (Right to buy) |
| 10 Sep 2026 |
8-K: Other Events
Biohaven Ltd. (the “Company,” “we” or “our”) is providing updates to the BHV-7000 program. We refer you to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for a description of the BHV-7000 program. |
| 26 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain confidential information contained in this exhibit has been omitted by means of redacting a portion of the text and replacing it with [***], pursuant to Regulation S-K Item 601(b)(10) of the Securities Act of 1933, as amended. Ce... |
| 14 Aug 2026 |
Form 3: Yetimoglu John, Director
Holds 6,250,000 shares of Common Shares |
| 14 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
NEW HAVEN, Conn., August 10, 2026 /PRNewswire/ – Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapi... |
| 10 Aug 2026 | 10-Q |
| 07 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026. Mr. Yetimoglu will serve in the class of directors whose term will expire at the C... |
| 17 Jul 2026 |
Form 3: Volles Warren Karl, Chief Legal Officer
Holds 248,212 shares of Common Shares |
| 09 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
NEW HAVEN, Conn., July 9, 2026 — Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has... |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 27 May 2026 |
8-K: Regulation FD Disclosure
© 2026 Biohaven, Ltd. All rights reserved. Trop2 ADC FGFR3 ADC CD30 ADC ONCOLOGY DEGRADERS TYK2/JAK1 INHIBITOR INFLAMMATION & IMMUNOLOGY TRPM3 ANTAGONIST KV7 ACTIVATORION CHANNEL T-ALFAMYOSTATIN TRORILUZOLEGLUTAMATE PROGRAMSCATEGORY May ... |
| 15 May 2026 | SCHEDULE 13G/A |
| 05 May 2026 |
8-K: Other Events
We have acted as counsel as to British Virgin Islands law to the Company in respect of the proposed issuance of up to US$350,000,000 in aggregate offering price of common shares in the Company with no par value (the "Shares") from time t... |
Loading...